Galapagos NV (GLPG.AS) - Now Lakefront Biotherapeutics - Deep Dive Research Report

Report date: 2026-05-18. Concalls used: Q1 2026 (May 7, 2026), FY2025 (February 24, 2026), Q3/9M 2025 (November 5, 2025), H1 2025 (July 23, 2025).

1. What the Company Does

Galapagos NV - as of May 8, 2026 legally renamed Lakefront Biotherapeutics NV - is a Belgian biotechnology company headquartered in Mechelen that has undergone one of the more dramatic identity crises in recent European biotech history. Understanding what the company does today requires understanding what it has been, because the present model is entirely a reaction to a string of failures in the preceding five years.

The company was founded in 1999 as a joint venture between Crucell, a Dutch gene therapy company, and Tibotec, a Belgian pharma company. Paul Stoffels - who would later lead it as CEO from 2022 to 2025 - was a co-founder. The original concept was to harness adenoviral vector technology to introduce human gene sequences into cell lines, knocking proteins in or out to identify novel drug targets at scale. This functional genomics platform was the company's core asset for the first decade of its life - a contract-research tool that was sold to pharmaceutical companies as a way to find new drug targets faster than traditional methods.

The platform produced filgotinib (brand name Jyseleca), a selective JAK1 inhibitor discovered internally. Filgotinib became the company's first commercial product, receiving EU marketing authorization for rheumatoid arthritis in 2020 and later for ulcerative colitis. In 2019, Gilead Sciences paid $3.95 billion upfront plus a $1.1 billion equity investment - a combined $5.1 billion - to gain 10-year co-development rights to Galapagos' entire pipeline. At that moment, Galapagos looked like one of Europe's premier drug discovery engines.

The story then hit turbulence. In 2020, the FDA rejected filgotinib for RA in the United States, citing fertility safety concerns at the high dose. Gilead retreated from the US filing and renegotiated its rights, returning European commercialization control to Galapagos. The remainder of the Galapagos pipeline under the Gilead umbrella largely disappointed - program after program failed to advance. The Gilead deal, once heralded as transformative, became a constraint: the exclusivity terms limited Galapagos' ability to pursue deals outside the Gilead framework. By 2022, Galapagos had no US commercial business, a slowly growing European Jyseleca franchise, and a pipeline that had essentially been reset.

Paul Stoffels joined as CEO in April 2022 with a new vision: pivot to cell therapy. He acquired CellPoint (€125 million, automated point-of-care CAR-T manufacturing) and AboundBio ($14 million, antibody discovery) and repositioned the company as a next-generation cell therapy developer. The logic was sound - decentralized, fresh CAR-T manufacturing with a seven-day vein-to-vein timeline could address the biggest practical limitations of first-generation CAR-T products. The programs showed early promise: GLPG5101 (CD19 CAR-T) achieved 97% complete response rates in relapsed/refractory indolent NHL.

But the cell therapy pivot then collapsed. In January 2025, Galapagos announced an intention to separate into two public companies: the cell therapy business as one entity and a new "SpinCo" M&A vehicle funded with €2.45 billion. By May 2025, the separation was abandoned. Henry Gosebruch, named as SpinCo CEO in April 2025, became CEO of the whole company in May 2025 when Paul Stoffels retired ahead of schedule. By October 2025, the board had decided to wind down cell therapy entirely - not sell it, wind it down - after a five-month strategic review found no viable acquirer.

What Galapagos is today is something new: an acquisition-funded clinical-stage biotechnology company with approximately €2 billion in cash (post the Ouro deal), a lead asset in gamgertamig (a BCMA/CD3 T-cell engager for autoimmune diseases), a legacy TYK2 inhibitor program it is trying to out-license, an annual royalty stream from Jyseleca via its acquirer Alfasigma, and a deal-by-deal partnership with Gilead that supplies both capital optionality and 25% of the company's equity as an anchor shareholder.

The core value proposition in the current model is this: the company has roughly €2 billion in remaining cash after the Ouro deal closes, a world-class dealmaking team led by a CEO (Gosebruch) who executed over 100 transactions at AbbVie, a Gilead relationship that can co-invest on deals and provide commercial infrastructure, and a new lead asset (gamgertamig) that has FDA Fast Track and Orphan Drug designations in two indications and is on a path to registrational trials by 2027. The specific problem gamgertamig addresses - autoimmune diseases mediated by pathogenic autoantibodies from long-lived plasma cells - is one where existing therapies like rituximab (which kills B cells but not plasma cells) and chronic immunosuppression leave a large population of patients inadequately treated or unable to sustain remission.

2. Business Segments

Galapagos/Lakefront is effectively a single-business company at this point of its evolution, with no meaningful revenue-generating segments. The cell therapy segment has been wound down. Jyseleca was sold. What exists is a clinical development portfolio supported by partnership capital. That said, there are three functional areas worth describing distinctly.

2a. Gamgertamig / Ouro Development Program

This is the company's primary asset and the reason the company will exist in its current form. In March 2026, Gilead acquired Ouro Medicines, a privately held biotech company that had developed gamgertamig (formerly OM336), for $1.675 billion upfront plus $500 million in milestones. Under an immediately-subsequent deal between Gilead and Galapagos, the two companies entered a 50/50 cost-sharing arrangement: Galapagos will pay approximately €713 million as its share of the upfront consideration (approximately half the $1.675 billion, adjusted for deal costs), plus 50% of any milestones. In exchange, Galapagos takes on the full development cost burden through initiation of registrational studies; development costs thereafter are split equally with Gilead. Gilead retains worldwide commercialization rights outside of Greater China (which is held by Keymed Biosciences). Galapagos will receive royalties of 20-23% of net sales.

The deal structure is notable for what it reveals about the Gilead relationship. Gilead is not a passive co-investor; the two companies had a pre-existing commercial and scientific infrastructure. Gilead acquiring Ouro and then immediately co-developing with Galapagos reflects an evolved partnership model: Galapagos provides the capital and development bandwidth for early-stage programs, Gilead provides commercialization. In the Q1 2026 call, CEO Gosebruch described the Gilead relationship as "a key strategic advantage and potential competitive differentiation" - their infrastructure means Lakefront doesn't need to build its own commercial organization, which extends the time its capital can fund development.

Gamgertamig itself is a BCMAxCD3 bispecific T-cell engager. It redirects the patient's own T cells toward cells expressing BCMA (B-Cell Maturation Antigen), which is expressed predominantly on plasmablasts and long-lived plasma cells. These cells are the factories for the autoantibodies that drive many antibody-mediated autoimmune diseases - conditions like immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), Sjögren's disease, and inflammatory myopathies. Conventional therapies (steroids, rituximab, IVIG) fail to eliminate these long-lived plasma cells, which sit in bone marrow niches and continue producing autoantibodies even after B-cell depletion. BCMA targeting attacks the problem at its source.

The key technical differentiator in gamgertamig is what Ouro (and Lakefront) call "detuning" the CD3 binding arm. Normal T-cell engagers bind CD3 on T cells with high affinity; this triggers potent T-cell activation, which is exactly what kills tumor cells in oncology. But in autoimmune patients who are not critically ill (unlike advanced myeloma patients), the resulting cytokine release syndrome can be dangerous enough to prohibit the therapy. Gamgertamig's CD3 arm was engineered to bind with lower affinity - enough to kill BCMA-positive cells, but with substantially reduced cytokine storm risk. In the Phase 1/2 studies covering over 60 patients across five indications including AIHA, ITP, dermatomyositis, and Sjögren's, the drug demonstrated rapid and durable complete responses (often drug-free remissions after a single treatment cycle) with a CRS profile that management describes as manageable and differentiated versus comparable programs.

2b. GLPG3667 (TYK2 Inhibitor) - Legacy Program Seeking a Partner

GLPG3667 is a selective inhibitor of TYK2 (Tyrosine Kinase 2), a signaling enzyme in the JAK family that transduces the type I/III interferon pathway and the IL-12/IL-23 pathway. It was discovered internally at Galapagos and reached Phase 3-enabling studies in two autoimmune indications: dermatomyositis and systemic lupus erythematosus.

In December 2025, Galapagos reported mixed results. In dermatomyositis (GALARISSO study), GLPG3667 met its primary endpoint: a statistically significant improvement in Total Improvement Score (TIS) at Week 24 versus placebo (p=0.0848, Δ=14.26 points, against a pre-specified 10% significance threshold). Secondary endpoints also showed meaningful improvement. Dermatomyositis is a rare autoimmune muscle disease with no FDA-approved treatments - the unmet need is significant.

In systemic lupus erythematosus (GALACELA study), the primary endpoint - dose-response analysis on the SRI-4 scale at Week 32 - was not met. Some secondary endpoints showed numerical improvements, and the company notes that final Week 48 data is due Q2 2026. TYK2 inhibition in SLE is an active area - Bristol-Myers Squibb's Sotyktu (deucravacitinib) is already approved for psoriasis via TYK2 inhibition, but the path to SLE is unproven for the mechanism.

Galapagos has indicated it is evaluating all strategic alternatives, including resumption of a partnering process, to advance GLPG3667 in dermatomyositis. The company does not intend to self-commercialize this asset; it is a potential milestone-bearing out-licensing opportunity. The TYK2 program costs management guided up to €40 million in 2026.

2c. Royalty Stream - Jyseleca / Filgotinib

When Galapagos sold the Jyseleca business to Italian pharma company Alfasigma in 2024 (€50 million upfront, €120 million in milestones, plus mid-single to mid-double digit royalties on European sales), it retained a royalty stream. Management has guided this royalty income at €15-20 million per year through the mid-2030s, when the Jyseleca patents are expected to expire in key European markets. This is not a business segment in any meaningful sense; it is a declining cash flow that partly offsets operating costs during the development phase.

3. Products and Business Detail

Gamgertamig (BCMAxCD3 T-cell engager)

Gamgertamig is a bispecific antibody - a single protein molecule engineered to bind two different targets simultaneously. One binding domain engages BCMA, expressed on plasmablasts and long-lived plasma cells. The other domain engages CD3, a component of the T-cell receptor complex on T lymphocytes. When gamgertamig brings a T cell into proximity with a BCMA-expressing plasma cell, the T cell kills it.

The detuned CD3 design is not cosmetic. Conventional CD3 binding arms - as found in Janssen's teclistamab (Tecvayli) for myeloma - are optimized for maximum T-cell activation because multiple myeloma patients are at terminal stage and require maximal cell kill. In autoimmune disease, the patient population is less compromised, the safety bar is higher, and regulatory agencies expect a tolerability profile suitable for conditions that are debilitating but not immediately fatal. By engineering reduced CD3 affinity, Ouro/Lakefront/Gilead positioned gamgertamig for the autoimmune indication set from the beginning - not as an afterthought.

Clinical program: Two basket studies are active.

1. NCT07083960 (autoimmune cytopenias) - evaluating AIHA, ITP, or both, across the US and Australia
2. NCT07229144 (broader autoimmune) - evaluating Sjögren's disease, dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and anti-synthetase syndrome

Regulatory designations:

• FDA Fast Track: ITP and AIHA (both)
• FDA Orphan Drug Designation: ITP and AIHA (both) These designations provide accelerated regulatory review, more frequent FDA interaction, and for ODD, 7-year market exclusivity in the US after approval.

Expected timeline: Registrational studies by 2027. Management cited data from over 60 patients as the basis for confidence.

GLPG3667 (TYK2 inhibitor, 150 mg daily dose)

Oral small molecule, once daily. TYK2 inhibitors work differently from older JAK inhibitors - they target the pseudokinase (JH2) domain rather than the active kinase domain, which provides greater selectivity. BMS's deucravacitinib works via this mechanism and was approved for psoriasis.

Completed trials:

• GALARISSO (dermatomyositis, 40 patients): Primary endpoint met
• GALACELA (SLE, ~186 patients): Primary endpoint not met; Week 48 follow-up ongoing

Dermatomyositis is a disease with a critical unmet need. The standard treatment involves long-term immunosuppressants (steroids, methotrexate, IVIG) and the disease often becomes steroid-dependent with progressive muscle weakness and distinctive skin rashes. The GALARISSO result, while statistically modest (pre-specified α=0.1 threshold rather than the more demanding 0.05), represents a clinical proof of concept in an indication with no approved drug.

Jyseleca (filgotinib) - divested but royalty-generating

Filgotinib is now owned by Alfasigma, which sells it in the EU for RA and UC. Galapagos retains royalty rights. The drug has some ongoing competitive pressures - rinvoq (AbbVie's upadacitinib, approved in more indications) is the market share leader in JAK inhibitors in Europe - but the royalty stream requires no investment from Galapagos/Lakefront.

Legacy CAR-T Programs - Terminated

GLPG5101 (CD19 CAR-T, ATALANTA-1 study) and GLPG5301 (BCMA CAR-T, PAPILIO-1 study) were both terminated as part of the cell therapy wind-down. Patients have been transitioned to the HESPERIA long-term follow-up study. The cell therapy manufacturing infrastructure (Leiden, Basel, Princeton, Pittsburgh, Shanghai) is being wound down, expected substantially complete by Q3 2026.

The point-of-care manufacturing model built around Lonza's Cocoon platform and Thermo Fisher's rapid sterility testing was technically innovative - seven-day vein-to-vein production versus 3-6 weeks for centralized manufacturers. However, the commercial model couldn't attract a buyer willing to fund it through to approval, and Galapagos lacked the capital concentration and commercial infrastructure to go it alone.

Three Preclinical Programs from Ouro

The Ouro portfolio includes three additional preclinical programs beyond gamgertamig. These have not been publicly described in detail. Management mentioned them as potential future pipeline depth - their advancement will depend on resource allocation decisions over the next 1-2 years.

4. Customers

Galapagos/Lakefront is a drug development company, not a commercial-stage business. Its "customers" are:

Gilead Sciences (strategic partner and co-investor): Gilead remains the central commercial relationship. The new deal structure means Gilead is both a capital co-investor (contributing 50% of the Ouro upfront) and the commercialization partner for gamgertamig. Gilead's 25% equity stake makes them the single largest shareholder. The standstill agreement limiting Gilead from acquiring more than 29.9% has expired (the original 10-year deal ran from 2019), so the relationship has been renegotiated to a deal-by-deal basis. In practice, Gilead's Devang Bhuva sits on the Galapagos board, providing direct oversight. The switching cost for Galapagos to find another commercialization partner is high - it would require Gilead's consent given their equity stake and board seat, and building an alternative commercial relationship would take years.

Alfasigma (Jyseleca): Pays royalties on European Jyseleca sales. No ongoing relationship beyond the contractual royalty mechanism.

Pharmaceutical company partners for GLPG3667: Galapagos is actively seeking a partner to take GLPG3667 forward in dermatomyositis. The typical deal structure in rare disease out-licensing is an upfront payment, development milestones, and royalties on net sales. The counterparties would be large pharma or specialty rare disease companies with existing neuromuscular or autoimmune franchises - AstraZeneca (RareBiologics), Sanofi (rare disease platform), UCB, or similar.

Patients and physicians: As a development-stage entity, commercial payer/prescriber relationships don't yet exist for gamgertamig. The relevant regulatory audience is the FDA (and EMA), where Fast Track and Orphan designations already provide a communication runway.

5. Competitive Landscape

The T-Cell Engager Autoimmune Space - Who is Racing Gamgertamig

The T-cell engager autoimmune class has attracted extraordinary capital since 2024. More than $10 billion in deal value has been committed to TCE and bispecific autoimmune assets since mid-2024, with over 40% of all pharma multispecific antibody deals targeting autoimmune and inflammatory diseases. The class is producing results that chronic immunosuppression and standard biologics cannot: durable, drug-free remissions in patients who have failed everything else.

Cullinan Therapeutics (CLN-978, CD19/CD3): The most closely watched clinical program in the TCE autoimmune space. CD19 targets the broad B-cell lineage; CLN-978 is in Phase 1 for SLE, RA, and Sjögren's. Q2 2026 data from Cullinan has been described by independent observers as "the defining catalyst for the entire class." CD19 and BCMA are not direct competitors - they target different parts of the B-cell/plasma cell axis - but they will compete for the same patient populations and the same payer/prescriber mindshare.

Candid Therapeutics (cizutamig, BCMAxCD3): The most direct clinical competitor to gamgertamig. Cizutamig is also a BCMA/CD3 bispecific targeting autoimmune diseases and has declared "clinical proof-of-concept." Candid has four TCE programs across 10 indications and has dosed 87 patients. The differentiation between gamgertamig and cizutamig is primarily in the CD3 detuning approach and the specific clinical data readout.

Sanofi / Kali Therapeutics (KT501, CD3/CD19/BCMA trispecific): Sanofi paid $180 million upfront to license KT501, which binds three targets simultaneously - CD3, CD19, and BCMA. The logic: dual B-cell targeting could provide deeper, more durable depletion. Currently in first-in-human studies. If it works, it could outcompete both BCMA and CD19 monospecifics.

AbbVie / Ichnos (ISB 2001, CD38/BCMA/CD3 trispecific): AbbVie paid $700 million upfront for ISB 2001, a trispecific designed for oncology but potentially applicable to autoimmune. Adds CD38 targeting (which hits a different plasma cell population than BCMA alone). AbbVie is treating this as primarily an oncology asset; the autoimmune application is secondary.

Janssen (teclistamab - Tecvayli): Already approved for relapsed/refractory multiple myeloma. Academic case series (N=10) in refractory autoimmune diseases showed clinical benefit in 9 of 10 patients, with 6 achieving drug-free remission. Teclistamab was not designed for autoimmune disease and lacks the detuned CD3 arm; its CRS profile is more significant. But it is already approved and available, creating an off-label competitive dynamic in severe autoimmune cases.

Barriers to entry for the class: Bispecific antibody engineering is technically demanding. Getting the dual binding right, manufacturing the molecule at scale, managing the immune effector biology in a new indication set, and running basket studies across multiple rare indications all require specialized knowledge that took Ouro/Galapagos/Gilead years to accumulate. The regulatory path for each indication requires separate clinical work. That said, the class is clearly proven enough that capital is flowing - this is not a niche with high secrecy barriers.

Where gamgertamig wins: Detuned CD3 arm gives it a differentiated safety profile for autoimmune populations. Orphan Drug and Fast Track designations provide a regulatory head start for ITP and AIHA. Gilead's commercialization infrastructure means faster path to market in approved indications. First published clinical data in AIHA and ITP specifically.

Where gamgertamig is exposed: Clinical stage - still Phase 1/2. The road to approval requires Phase 2/3 basket studies in multiple indications, each requiring its own regulatory interaction. Cizutamig and others are close behind. If a competitor achieves first approval in an autoimmune indication, the field's risk perception changes, which could be positive (validation) or negative (pricing pressure, payer fatigue).

TYK2 Competitive Landscape

Bristol-Myers Squibb (Sotyktu / deucravacitinib): Already approved for plaque psoriasis via TYK2 inhibition. BMS is running trials in SLE and psoriatic arthritis. If Sotyktu achieves SLE approval (results expected 2026-2027), it validates the mechanism but also makes partnering GLPG3667 in SLE harder unless GLPG3667 shows a differentiated profile.

AstraZeneca (tyrosine kinase inhibitor programs): Multiple JAK/TYK2 programs ongoing.

Almirall and others: Several smaller TYK2 programs in dermatology.

The DM indication is less contested - dermatomyositis is rare (approximately 10,000 US patients, similar in Europe), and no TYK2 inhibitor is specifically in Phase 3 there. This is Galapagos' most valuable partnering chip for GLPG3667.

6. Industry

T-Cell Engager / Bispecific Antibody Market

The bispecific antibody market was valued at approximately $8.9 billion in 2025 and is growing to $16.8 billion by 2035 (CAGR ~6.5%). Within bispecifics, T-cell engagers specifically represent the fastest-growing sub-segment, with the T-cell engager market valued at $2.5 billion in 2025 and projected to reach $18.8 billion by 2034 (CAGR 21.2%). The autoimmune indication set is the newest and fastest-growing slice of TCE activity.

Demand is driven by three convergent forces:

1. Mechanism validation: CAR-T cells (a cellular form of the same BCMA-targeting logic) have now shown durable remissions in severe autoimmune patients who failed all other treatments, including in academic datasets. This has de-risked the plasma cell depletion concept substantially.
2. Unmet need: Conditions like ITP, AIHA, myositis, and severe SLE represent a large population of patients who cannot achieve sustained remission on available therapies and face life-threatening disease activity or cumulative toxicity from long-term steroids and immunosuppressants.
3. Off-the-shelf advantage: Unlike CAR-T, which requires patient cell collection and manufacturing, T-cell engagers are manufactured like conventional antibodies - no patient-specific production. This dramatically improves scalability, cost, and logistics.

Regulatory Environment

FDA's Fast Track designation (held by gamgertamig for ITP and AIHA) provides rolling review and more frequent FDA interaction. Orphan Drug Designation provides a seven-year post-approval market exclusivity window in the US and tax credits for clinical development costs. For rare autoimmune cytopenias in particular, the regulatory path is relatively well-defined, with clear surrogate endpoints (platelet count for ITP, hemoglobin for AIHA) that can support accelerated approval.

The EMA has analogous mechanisms for rare diseases (Orphan Medicinal Product designation) that provide 10-year market exclusivity in the EU.

Autoimmune Disease Market Context

The autoimmune therapeutics market overall is valued in the hundreds of billions of dollars globally and is one of the largest pharmaceutical verticals, dominated by TNF inhibitors (AbbVie's Humira franchise), IL-17/23 inhibitors, and JAK inhibitors. The BCMA/plasma cell depletion niche is different: it addresses a more severe, more refractory patient subpopulation where the addressable patient base is smaller (rare disease level) but the pricing power and medical urgency are both significantly higher.

Cyclicality

Drug development companies of this type are not economically cyclical in the traditional sense. Their fate is binary at each clinical readout and depends on scientific rather than macro factors. However, biotechs are rate-sensitive - higher rates reduce the net present value of future cash flows from development assets, which is reflected in sector-wide multiples. The key external variable for Lakefront is the availability and pricing of comparable acquisitions: in a risk-off biotech market, early clinical-stage assets become cheaper, which actually benefits an acquirer with €2 billion in cash.

7. Growth Triggers

All triggers sourced from the four concalls listed above.

• Gamgertamig Phase 2/3 data readout in AIHA and ITP (anticipated 2026-2027): The Phase 1/2 basket studies are ongoing. Clean data in the autoimmune cytopenia indications - the fastest regulatory path to approval - could directly enable registrational study initiation in 2027. "Detuned CD3 arm...significantly reducing the CRS risk...potent BCMA binding for deep B-cell depletion." (Q1 2026 concall, May 7, 2026)

• Gamgertamig registrational studies initiation by 2027: Management explicitly guided this timeline. "Expected to enter registrational trials as early as 2027." (Q1 2026 concall, May 7, 2026) This is the key value-creation milestone for the lead asset.

• SLE final data from GALACELA study (Q2 2026): The Week 48 data is expected in Q2 2026. A positive outcome would meaningfully improve the partnering prospects for GLPG3667 in SLE, which management described as an indication with significant commercial potential. (FY2025 concall, February 24, 2026)

• GLPG3667 partnership announcement in dermatomyositis: Following the positive GALARISSO result, management indicated they were resuming the partnering process. A deal announcement for the DM program specifically would validate the asset's commercial potential and potentially bring in upfront and milestone payments. "Evaluating all strategic alternatives, including resumption of the partnering process." (FY2025 concall, February 24, 2026; confirmed Q1 2026 concall, May 7, 2026)

• Cell therapy wind-down completion by Q3 2026: The wind-down is expected substantially complete by Q3 2026. Completion reduces operational complexity and cash burn, and removes the overhang of an ongoing restructuring on the company's operating cost base. "The wind-down [will be] substantially complete by Q3 2026." (FY2025 concall, February 24, 2026)

• Second transformational acquisition: Gosebruch has signaled that gamgertamig is not the only deal Lakefront plans to execute. With €2 billion in remaining cash after the Ouro deal and a stated intent to build a pipeline through acquisitions, a second major clinical-stage asset acquisition is explicitly on the agenda. "We have the resources, the relationships, and the expertise to do more." (Q1 2026 concall, May 7, 2026) Repeated at JPMorgan Healthcare Conference (January 2026).

• Shareholder return execution (up to €150M): In connection with the Gilead deal renegotiation and the Ouro acquisition, management committed to returning up to €150 million to shareholders. The mechanism (buyback) was authorized at the April 28, 2026 EGM. Actual execution is a near-term catalyst for shareholder sentiment. (Q1 2026 concall, May 7, 2026)

"We have transformed our management team and board, repositioned our portfolio, added an exciting set of new pipeline programs." - CEO Henry Gosebruch, Q1 2026 concall

8. Key Risks

R&D / Clinical Risk in Gamgertamig

Phase 1/2 data, while encouraging, is not Phase 3 data. The autoimmune TCE class is early - no BCMA/CD3 TCE has been approved for an autoimmune indication. The "detuned" CD3 arm is an engineering approach that reduced CRS in the population studied (60+ patients across multiple indications), but registrational trials in larger populations may reveal adverse event patterns not visible at Phase 1 scale. The mechanism - T-cell cytotoxicity of plasma cells - is potent, and the question of whether immune reconstitution (B cells and plasma cells recover after depletion) is sustained vs. transient is a key long-term efficacy question.

The risk is moderate probability and high impact: if the Phase 2/3 data disappoints, the primary asset fails and the company falls back on cash, the TYK2 program, and the capacity to do another deal.

Deal Execution Dependency

Lakefront's entire value proposition rests on the management team's ability to identify, acquire, and advance the right clinical-stage assets at the right price. Gosebruch's AbbVie track record (100+ transactions) is cited constantly, but executing deals with precision while maintaining scientific rigor in a competitive market where large pharma companies and well-capitalized crossover funds are hunting the same assets is genuinely difficult. The Ouro deal cost more than €700 million; a string of mispriced acquisitions would be capital-destructive in a way that is hard to reverse. There is no internal pipeline of early-stage assets to fall back on; the company's seed stage was terminated when cell therapy was wound down.

Gilead Dependency and Misalignment Risk

Gilead owns 25% of Lakefront. Gilead holds worldwide commercialization rights to gamgertamig outside Greater China. If Gilead's priorities shift - if Gilead itself faces strategic pressures, or if the autoimmune TCE category doesn't fit their commercial strategy at the time of approval - the commercialization arrangement could be slower or less effective than anticipated. The board seat held by Gilead (Devang Bhuva) ensures Gilead has visibility into Lakefront's pipeline and deal flow, which creates an information asymmetry risk: Gilead could in theory decline to co-invest in a deal Lakefront identifies, or prioritize different assets.

Gosebruch explicitly addressed this in the Q1 2026 call, framing the Gilead relationship as "potentially competitive differentiation" - but a constraint can also masquerade as an advantage.

Competitive Speed Risk in Autoimmune TCE

If Cullinan's CLN-978 (CD19/CD3), Candid's cizutamig, or another TCE achieves first approval in an autoimmune indication before gamgertamig, it would set the pricing and efficacy bar for the field, potentially limit payer willingness to pay premium prices for a second entrant, and reduce the novelty of the registration story. CD19/CD3 and BCMA/CD3 target different cells (broad B-cell lineage vs. plasma cells specifically), so they may be complementary rather than strictly competitive - but the payer and prescriber attention is finite.

GLPG3667 Partnering Failure Risk

If no partner emerges for the TYK2 program, the asset either gets shelved (writing off development costs) or Lakefront funds it alone (drawing down cash). The DM result was compelling but was conducted with a 10% significance threshold rather than the typical 5% - some partners will view this as a marginal result requiring confirmatory data before committing capital. In SLE, the primary endpoint was missed.

Cash Burn Rate and Deployment Timing Mismatch

After the Ouro deal, Lakefront's cash guide drops to €1.975-2.05 billion. The development cost through registrational study initiation for gamgertamig is Lakefront's responsibility; Gilead shares costs only after that point. If registrational studies take longer to design or initiate than expected, the runway of the remaining cash extends, but so does the period without near-term data catalysts.

Legacy Culture and Operational Transformation

The company is shrinking from hundreds of employees to approximately 35-40 by end 2026. The transition involves not just headcount reduction but elimination of entire functions (cell therapy manufacturing, clinical operations for CAR-T, former discovery platform). The remaining organization must retain the institutional knowledge and deal-execution capability that the model requires while shedding the people and systems built for a different strategy. This is a management execution risk that is difficult to evaluate from the outside.

9. Walk the Talk

Concalls used:

1. H1 2025 (July 23, 2025)
2. Q3/9M 2025 (November 5, 2025)
3. FY2025 (February 24, 2026)
4. Q1 2026 (May 7, 2026)

Starting with the H1 2025 call in July 2025, Henry Gosebruch - newly installed as CEO just two months prior - laid out what he said his priorities were: "pursue transformational transactions to build a pipeline and maximize cash available for business development." He was operating against a backdrop where the separation plan (announced in January 2025) had just been abandoned in May 2025, and the cell therapy business was being evaluated for strategic alternatives. In the H1 2025 call, the CD19 CAR-T program (GLPG5101) was still positioned as a live asset with compelling data - 97% complete response in indolent NHL, BLA filing anticipated 2028, approval expected 2029. There was no explicit promise about what would happen with cell therapy, only that "strategic alternatives" were being assessed.

By the Q3/9M 2025 call in November, the picture had changed completely. The five-month strategic review had concluded with no viable acquirer for the cell therapy business, and management announced the wind-down.

"After a five-month process, there were no viable proposals presented that would reasonably support the business going forward." - Q3 2025 concall, November 5, 2025

This is where the credibility analysis becomes nuanced. On one hand, Gosebruch did not overpromise in July - he never said a sale was coming, only that alternatives were being assessed. On the other hand, the pattern of strategic reversal across the 18 months preceding his appointment is striking: the company announced a separation (January 2025), reversed it (May 2025), began a sale process (H1 2025), wound down the cell therapy business when the sale failed (November 2025). Investors who paid for the cell therapy pivot absorbed losses in the form of €275 million in wind-down charges (including €228 million in impairments).

Gosebruch's own conduct across these four concalls has been characterized by directness when things don't work. He communicated the wind-down decision promptly when it was made. He provided specific guidance on cash positions and narrowed those ranges as time passed - the year-end 2025 cash guidance of €2.975-3.025 billion from the Q3 2025 call landed at €2.998 billion, essentially in the middle of the guided range. The year-end 2025 guidance issued at the Q3 call proved accurate to within €23 million.

At the FY2025 call in February 2026, management had a specific and meaningful delivery moment: the GLPG3667 data. The Q3 2025 call had noted that the Phase 3-enabling studies were "fully enrolled" and data was expected "by early 2026, ahead of original expectations." The data arrived in December 2025 - delivered early as promised. The dermatomyositis result met its primary endpoint. The SLE result missed. Management did not spin the SLE miss; they reported it plainly and framed the ongoing Week 48 data as relevant supplementary information.

"Our new senior leadership team...focused on the Company's transformation to better position Galapagos for long-term value creation." - FY2025 concall, February 24, 2026

The capital allocation guidance across these calls has been the most consistently accurate element of management communication. Cash position guidance from each call has landed within the guided range or narrower when updated. The cell therapy wind-down cost range was initially guided at €150-200 million (Q3 2025) and subsequently narrowed to €125-175 million (FY2025), with the lower bound reflecting better-than-expected restructuring outcomes.

By Q1 2026, the Ouro acquisition announcement represented Gosebruch's first major deployment decision. The framing was confident:

"We identified the best alternative out there and has the potential to be first in class." - Q1 2026 concall, May 7, 2026

This is forward-looking and will take years to validate. But the specific claims around gamgertamig - FDA Fast Track, Orphan Drug designation, 60+ patients dosed, planned 2027 registrational studies - are all publicly verifiable facts consistent with the Ouro press releases.

Assessment: Management under Gosebruch has been reliable on what they can control (cash management, guidance ranges, timing of cost restructuring) and honest on what didn't work (cell therapy sale failed, SLE endpoint missed). They have not fabricated outcomes or buried misses in footnotes. The credibility concern is structural rather than behavioral: the management team's tenure is short (less than a year for most), the strategy has pivoted dramatically, and the test of their deal execution capability has only just begun with the Ouro acquisition. The track record is too short to validate, but the communication quality across these four calls is strong.

10. Shareholder Friendliness Index

Galapagos/Lakefront has never paid a dividend. In 2023, no dividend was declared. In 2024, no dividend was declared. In 2025, no dividend was declared. For a pre-commercial biotech with a development-stage pipeline and a €3 billion cash position that was being actively deployed for acquisitions, this is consistent with standard practice rather than an unusual posture. The company has not historically framed itself as a capital-returner.

On buybacks, the history is also not favorable. The GuruFocus 3-year average share buyback ratio for GLPG has been negative - meaning the company has been a net issuer of shares historically, primarily through stock-based compensation (RSU and option programs for employees and directors). Shares outstanding were approximately 65.9 million as of late 2024, and there is no evidence of historical open-market buyback execution prior to 2026. The April 2026 EGM authorized a 10% buyback program (up to approximately 6.6 million shares), and management committed in the Q1 2026 concall to potentially returning up to €150 million to shareholders in connection with the Ouro deal structure. This represents a meaningful step toward capital return for the first time in the company's history.

Verdict: Hoards Capital - the company has historically prioritized R&D and M&A deployment over shareholder returns, has never paid a dividend, has been a net diluter through compensation programs, and the first buyback authorization only arrived in 2026 as part of a specific deal structure. The €150 million return commitment is new and positive, but it is conditional and represents a single gesture rather than an established pattern.

11. Insider Activities

Galapagos NV is incorporated in Belgium and listed on Euronext Amsterdam and Brussels, with an ADR on Nasdaq. For PDMR (Persons Discharging Managerial Responsibilities) transactions, the primary regulatory disclosure framework is EU Market Abuse Regulation (MAR) Article 19, with filings reported to and published by the FSMA (Autoriteit Financiële Markten for the Netherlands or the Belgian Financial Services and Markets Authority, depending on jurisdiction). The relevant FSMA managers' transactions database is at fsma.be/en/transaction-search.

Attempts made to locate primary source data:

• Direct fetch of the FSMA transaction-search database (fsma.be): Connection failed (socket error).
• Direct fetch of FSMA's managers-and-directors-transactions page: Connection failed (socket error).
• Fetch of the Lakefront/Galapagos transparency notices page: Returned institutional shareholder filings (>5% thresholds under Belgian Transparency Law) only, not PDMR transactions.
• Barchart insider trades page (which tracks SEC Form 4 filings for the US ADR): Confirmed zero transactions - expected, since the underlying shares are Euronext-listed and not subject to SEC Form 4 reporting.
• OpenInsider and similar US aggregators: No results for GLPG.

Large shareholder movements (from transparency notices, last 12 months):

These are not PDMR transactions; they are institutional shareholder threshold filings. Included here for completeness.

EcoR1 Capital (a healthcare-focused hedge fund) is noted as holding approximately 10.77% as of September 2024. Gilead Sciences has held approximately 25% continuously since the 2021 transparency filing.

PDMR transaction data for directors and officers is not accessible from the FSMA or AFM primary source within this search budget. The FSMA database is a dynamic web application that requires interactive searching and was not accessible via the fetch tools available. Anyone seeking current and complete PDMR transaction data should query the FSMA transaction-search database directly at fsma.be, using "Galapagos" as the issuer search term, with a date range of May 2025 to May 2026.

Net assessment: Based on available data, no meaningful insider buying or selling pattern can be confirmed at the director/officer level. The institutional shareholder data shows Bank of America actively trading around the 5% threshold (likely derivatives-related positioning or index rebalancing, not conviction signal), EcoR1 holding a large dedicated position (~10.77%), and Gilead anchored at ~25%. The absence of visible PDMR buying in the available sources is noteworthy but not conclusive - the FSMA database access failure means absence of evidence rather than evidence of absence.

12. Scenarios

Bull Case

The Ouro acquisition turns out to be the right bet at the right price. Gamgertamig's Phase 2/3 data in ITP and AIHA, expected to enable registrational trial initiation in 2027, shows the same transformative single-cycle remission profile seen in the Phase 1/2 data across a broader population, and the detuned CD3 arm holds up - CRS remains low and manageable, and regulators grant accelerated approval in at least one indication within 2-3 years of trial start. The autoimmune TCE category validates across the board as Cullinan and others also generate positive data, lifting the entire class. Galapagos/Lakefront is positioned as the only BCMA/CD3 TCE with prior Orphan Drug designation and a pre-established commercialization partnership at Gilead, which translates to faster prescription uptake than competitors. Meanwhile, a GLPG3667 partnership for dermatomyositis is announced, bringing a multi-hundred-million-euro upfront payment that partially offsets the cash deployed in Ouro. Gosebruch executes a second material deal from the remaining €2 billion cash in 2027, adding pipeline depth in a complementary indication. The company enters the early 2030s with two approved assets and three programs in the clinic, funded through to profitability.

Base Case

Gamgertamig advances to registrational studies in 2027 as guided. Phase 2/3 data is positive but takes time - perhaps approval arrives in a single rare autoimmune cytopenia indication (ITP or AIHA) by 2030 or 2031. Gilead launches the drug in the US with a premium orphan pricing strategy; Lakefront collects 20-23% royalties. The SLE GALACELA Week 48 data (Q2 2026) is mildly positive but insufficient to fully validate the indication without a Phase 3; a TYK2 partnership for dermatomyositis is signed in 2026-2027 for a modest upfront and future milestones. A second acquisition happens with the remaining cash but in 2027-2028, by which time the cash position is lower and deal economics are less favorable. The company operates as a lean, Gilead-partnered clinical platform, profitable on interest income and Jyseleca royalties in the near term, with the first commercial royalties from gamgertamig arriving in the early 2030s.

Bear Case

The autoimmune TCE class works, but gamgertamig specifically underperforms in larger Phase 2/3 populations - perhaps because the detuned CD3 arm, while safer, is also less potent than hoped, and complete response rates drop significantly versus the Phase 1/2 data. A competitor (cizutamig or a CD19/CD3 engager) achieves first approval in an autoimmune indication before gamgertamig reaches registrational readout, reframing gamgertamig as a second-entrant with a harder pricing case to make. The GLPG3667 partnering process fails - no buyer wants a TYK2 program in a SLE indication where BMS's Sotyktu already leads. Lakefront's management team, having invested €700+ million in Ouro, deploys more cash into a second acquisition that also disappoints, leaving the company with a depleted cash position, two underperforming assets, and no internal pipeline to rebuild from. The Gilead relationship becomes a constraint rather than an advantage - their 25% stake and commercialization rights create friction around deal negotiations with other potential partners. By 2029, the company is back to evaluating its strategic alternatives, with a significantly smaller cash position, a Gilead shareholder who may not agree with the new strategy, and a limited window to execute before cash runway becomes a concern.

Sources consulted: Galapagos/Lakefront Biotherapeutics IR (lakefrontbio.com), Annual Report 2025 (reports.glpg.com), Q1 2026 earnings call summary (Investing.com), FY2025 earnings call (Insider Monkey / GlobeNewswire), Q3/9M 2025 earnings call (Investing.com / GlobeNewswire), H1 2025 press release (GlobeNewswire), GLPG3667 results (Lakefront Biotherapeutics), Ouro Medicines / Gilead acquisition (Ouro Medicines PR, BusinessWire), FSMA transparency notices (Lakefront), Wikipedia founding history (Wikipedia), T-cell engager market data (InsightAce Analytic, Custom Market Insights), competitive landscape (BioStockInfo).